CellPraxis® Bioengenharia is a platform corporation dedicated to translating research into viable therapeutic tools in regenerative and individualized medicine.


CellPraxis® offices in Brazil and in the United States gather a team of experts in new product development management, science, regulatory, IP and market.


CellPraxis® may be considered among the most advanced corp in this new Era of Cell and Tissue Based Therapies.

Cellpraxis® Bioengenharia

ReACT®, the first product of CellPraxis®, comprises a specific cellular formulation, indicated for treatment of refractory angina. ReACT® has been clinically tested and showed excellent results in Brazil.


ReACT® is a standardized medical procedure in which a bio-infusion of a specific cellular formulation (MonoCell®) into ischemic myocardium is performed, promoting neoangiogenesis and consequent myocardial reperfusion.





Clinical (pain) and functional (scintigraphy) improvement with statistical significance;

Improvement of patient's quality of life;

Decrease of medical costs;

Standardized inclusion criteria;

Specific cellular preparation (MonoCell®) with standardized bio-infusion;






2015 © Axis Biotec Brasil. All rights reserved

Av. Carlos Chagas Filho, 791 Cidade Universitária -

Ilha do Fundão / Rio de Janeiro – RJ/ Brazil, 21.941-904

T: 55 21 3035-6950 / 55 21 2142-7777 / F: 55 21 2142-7734

Desenvolvido por Ramosdesign